Heterocyclic compounds and methods of making and using thereof

Details Heterocyclic compounds and methods of making and using thereof Heterocyclic compounds and methods of making and using thereof

2004-10-28

2008-11-25

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S157000

Reexamination Certificate

active

07456288

ABSTRACT:
Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4668218 (1987-05-01), Virtanen
patent: 4859581 (1989-08-01), Nicolson et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5458135 (1995-10-01), Patton et al.
patent: 5514670 (1996-05-01), Friedman et al.
patent: 5770222 (1998-06-01), Unger et al.
patent: 5770637 (1998-06-01), Vanderlaan et al.
patent: 5814599 (1998-09-01), Mitragotri et al.
patent: 5837832 (1998-11-01), Chee et al.
patent: 5849695 (1998-12-01), Cohen et al.
patent: 5874219 (1999-02-01), Rava et al.
patent: 6028088 (2000-02-01), Pershadsingh et al.
patent: 6156501 (2000-12-01), McGall et al.
patent: 6197599 (2001-03-01), Chin et al.
patent: 6218122 (2001-04-01), Friend et al.
patent: 6239209 (2001-05-01), Yang et al.
patent: 6263287 (2001-07-01), Zheng et al.
patent: 6273913 (2001-08-01), Wright et al.
patent: 2001/0014461 (2001-08-01), Hutchens et al.
patent: 2001/0034023 (2001-10-01), Stanton et al.
patent: 2001/0039016 (2001-11-01), Waldman et al.
patent: 2002/0051730 (2002-05-01), Bodnar et al.
patent: 2002/0086282 (2002-07-01), Pillarisetti et al.
patent: 0237507 (1987-09-01), None
patent: WO 94/06498 (1994-03-01), None
patent: WO 94/08552 (1994-04-01), None
patent: WO 94/16970 (1994-08-01), None
patent: WO 97/25086 (1997-07-01), None
patent: WO 97/38731 (1997-10-01), None
patent: WO 98/35888 (1998-08-01), None
patent: WO 93/21232 (1999-10-01), None
patent: WO 00/67776 (2000-11-01), None
patent: WO 01/77668 (2001-10-01), None
patent: WO 01/94946 (2001-12-01), None
patent: WO 02/23197 (2002-03-01), None
patent: WO 02/26139 (2002-04-01), None
patent: WO 02/26271 (2002-04-01), None
patent: 02/47687 (2002-06-01), None
Brownlee, M., et al. Nonensymatic Glycosylation and the Pathogensis of Diabetic Complications, Annals of Internal Medicine, Oct. 1984, 527-537, 101 (4), The American College of Physicians, Philadelphia, Pennsylvania, U.S.A.
Yang, C. et al., Advanced Glycation End Products Up-Regulate Gene Expression Found in Diabetic Glomerular Disease, Proceedings of the National Academy of Sciences of the United States of America, Sep. 1994, 9436-9440, vol. 91 (20), The National Academy of Sciences, Washington, D.C., U.S.A.
Tanji, N. et al., Expression of Advanced Glycation End Products and Their Cellular Receptor RAGE in Diabetic Nephropathy and Nondiabetic Renal Disease, Journal of the American Society of Nephrology, 2000, 1656-1666, vol. 11, No. 9, The American Society of Nephrology, Washington, D.C., U.S.A.
Schmidt, A.. et al., Activation of Receptor for Advanced Glycation End Products: A Mechanism for Chronic Vascular Dysfunction in Diabetic Vasculopathy and Atherosclerosis, Circulation Research, Mar. 1999, 489-497, vol. 84 (5), American Heart Association, U.S.A.
Yano, M. et al., Immunohistochemical Localization of Glycated Protein in Diabetic Rat Kidney, Diabetes Research Clinical Practice, 1990, 215-219, vol. 8 (3), Elsevier Science Publishers B.V.
Cohen, M. et al., Role of Amadori-Modified Nonenzymatically Glycated Proteins in the Pathogenesis of Diabetic Nephropathy, Journal of the American Society of Nephrology, 1996, 183-190, vol. 7, No. 2, The American Society of Nephrology, Washington, D.C., U.S.A.
Brownlee, M. et al., Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking, Science, 1986, 1629-1632, vol. 232, The American Association for the Advancement of Science, Washington, D.C.
Li, Y. et al., Prevention of Cardiovascular and Renal Pathyology of Aging by the Advanced Glycation Inhibitor Aminoguanidine, Proceedings of the National Academy of Sciences of the United States of America, Apr. 1996, 3902-3907, 93, The National Academy of Sciences, Washington D.C., U.S.A.
Piercy, V. et al., Potential Benefit of Inhibitors of Advanced Glycation End Products in the Progression of Type II Diabetes: A Study with Aminoguanidine in C57/BLKsJ Diabetic Mice, Metabolism, Dec. 1998, 1477-1480, vol. 47 (12), W. B. Saunders Company.
Yamamoto, Y. et al., Roles of the Age-Rage System in Vascular Injury in Diabetes, Annals of the New York Academy of Sciences, 2000, 163-172, 902 (1), The New York Academy of Sciences, U.S.A.
Wautier, J. et al., Receptor-Mediated Endothelial Cell Dysfunction in Diabetic Vasculopathy. Soluble Receptor for Advanced Glycation End Products Blocks Hyperpermeability In Diabetic Rats, Journal of Clinical Investigation, Jan. 1996, 238-243, vol. 97 (1), The American Society for Clinical Investigation, Ann Arbor, Michigan, U.S.A.
Schmidt, A.. et al., Advanced Glycation End Products Interacting with Their Endothelial Receptor Induce Expression of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Cultured Human Endothelial Cells and in Mice. A Potential Mechanism for the Accelerated Vasculopathy of Diabetes, Journal of Clinical Investigation, 1995, 1395-1403, vol. 96 (3), The American Society for Clinical Investigation, Ann Arbor, Michigan, U.S.A.
Park, L. et al., Suppression of Accelerated Diabetic Atherosclerosis by the Soluble Receptor for Advanced Glycation Endproducts, Nature Medicine, Sep. 1998, 1025-1031, vol. 4 (9), Nature Publishing Group, New York, New York, U.S.A.
Taguchi, A. et al., Blockage of RAGE-Amphoterin Signalling Suppresses Tumour Growth and Metastases, Nature, 2000, 354-360, vol. 405, Nature Publishing Group, New York, New York, U.S.A.
Hofmann, M. et al., RAGE Mediates A Novel Proinflammatory Axis: A Central Cell Surface Receptor for s100/Calgranulin Polypeptides, Cell, Jun. 1999, 889-901, vol. 97 (7), Cell Press, U.S.A.
Yan, S. et al., Amyloid-β Peptide-Receptor for Advanced Glycation End Product End Product Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease, Proceedings of the National Academy of Sciences of the United States of America, May 1997, 5296-5301, vol. 94 (10), The National Academy of Sciences, Washington D.C., U.S.A.
Lander, H. et al., Activation of the Receptor for Advanced Glycation End Products Triggers a p21 (ras)-dependent Mitogen-Activated Protein Kinase Pathway Regulated by Oxidant Stress, Journal of Biological Chemistry, Jul. 1997, 17810-17814, vol. 272 (28), The American Society for Biochemistry and Molecular Biology.
Thornalley, P., Cell Activation by Glycated Proteins, AGE Receptors, Receptor Recognition Factors and Functional Classification of AGEs, Cellular Molecular Biology, 1998, 1013-1023, vol. 44 (7), France.
Orford, J. et al., The Comparative Pathobiology of Atherosclerosis and Restenosis, American Journal of Cardiology, Aug. 2000, 6H-11H, vol. 86, (4) (2), Excerpta Medica, Inc.
Bult, H., Restenosis: A Challenge for Pharmacology, Trends in Pharmocological Science, Jul. 2000, 274-279, vol. 21 (7), Elsevier Science Ltd., United Kingdom.
Schwartz, S., Smooth Muscle Migration in Atherosclerosis and Restenosis, Journal of Clinical Investigation, Jun. 1997, 2814-2816, vol. 99 (12), The American Society for Clinical Investigation, Ann Arbor, Michigan, U.S.A.
Peyrottes, S. et al, Oligodeoxynucleoside Phosphoramidates (P-NH2): Synthesis and Thermal Stability of Duplexes with DNA and RNA Targets, Nucleic Acids Research, May. 1996, 1841-1848, vol. 24 (10), Oxford University Press, United Kingdom.
Chaturvedi, S. et al., Stabilization of Triple-Stranded Oligonucleotide Complexes: Use of Probes Containing Alternating Phosphodiester and Stereo-Uniform Cationic Phosphoramidate Linkages, Nucleic Acids Research, Jun. 1996, 2318-2323, vol. 24 (12), Oxford University Press, United Kingdom.
Beaucage, S. et al., Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for D

Affiliated with

Also associated with

Rating

Heterocyclic compounds and methods of making and using thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compounds and methods of making and using thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds and methods of making and using thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4025326